Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Study summary

Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study. The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedAllogeneic natural killer (NK) cell

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · EGFR · HER2

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 21, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?4 U.S. locations

Locations may change over time.

Who runs it?Fate Therapeutics

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Fate Therapeutics
Interventions being studied: Genetic: Allogeneic natural killer (NK) cell

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Biomarkers

EGFR→HER2→

Treatment approach

Immunotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Subjects who received an allogeneic, iPSC-derived NK cell in a Fate Therapeutics interventional study
Subjects who have provided Informed consent prior to their study participation

Reasons someone may not be able to joinExclusion criteria

Not Applicable

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

UCSD Moores Cancer CenterSan Diego, California
University of Minnesota Masonic Cancer CenterMinneapolis, Minnesota
Hackensack University Medical CenterHackensack, New Jersey
MD Anderson Cancer CenterHouston, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 21, 2023. Always confirm current availability with the study team.

View original record ↗